Abstract: OBJECTIVE To detect the expression of vascular endothelial growth factor-A(vascular endothelial growth factor-A) in serum and subcutaneous tumors of nude mices with Lewis lung carcinoma cell after intervention by bevacizumab. METHODS Thirty-two male BALB/c nude mices were equally randomed into control group, bevacizumab group, cisplatin group, and bevacizumab combined with cisplatin group after they were transplanted Lewis lung carcinoma cell and appeared subcutaneous tumor. After 3 weeks by administration, the mices were killed, and the expression of VEGF-A was detected by ELISA in serum and transplated tumor, and transplated tumor were maked into pathological section to obverse the vessel, and the expression of VEGF-A in transplated tumor was detected by immunohistochemical method. RESULTS The VEGF-A expression of serum in 3 medication groups was significantly lower than that in control group(P<0.05). The VEGF-A expression of subcutaneous tumors in 3 medication groups was lower than that in control group, the difference between bevacizumab group and control group, and between bevacizumab combined with cisplatin group and control group were significant(P<0.05). According to pathology, the transplant tumor of 3 medication groups had less necrosis and less blood vessels than the controled group. The necrosis and blood vessels of bevacizumab combined with cisplatin group was less than bevacizumab group, and the blood vessel of bevacizumab group was less than cisplatin group, but there was no significance in necrosis between bevacizumab group and cisplatin group. The positive number of VEGF-A of serum subcutaneous tumors in 3 medication groups was less than this in control group, and the whole difference was significant(P<0.05). CONCLUSION Bevacizumab can inhibit the growth of Lewis lung cancer, which is related to bevacizumab reduces the expression of VEGF-A, and cisplatin can enhance the effect. What’s more, the more expression of VEGF-A, the more vessel in subcutaneous tumor.